Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s43556-020-00018-9 http://scihub22266oqcxt.onion/10.1186/s43556-020-00018-9 C7700809!7700809 !34765997     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34765997 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Mol+Biomed 2020 ; 1 (1 ): 14 Nephropedia Template TP {{tp|p=34765997 |t=2020. Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences |pdf=|usr=}}{{34765997 }} gab.com Text Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences JO: Mol Biomed http://www.kidney.de/pget.php?&tw=1&pmid=34765997 #FOAvip The global pandemic of COVID-19 has attracted extensive drug searching interets for the new coronavirus SARS-CoV-2. Although currently several of clinically used "old" drugs have been repurposed to this new disease for the urgent clinical investigation, there is still great demand for more effective therapies for the anti-infections. Here we report the discovery that an "old" drug Emetine could potently inhibit SARS-CoV-2 virus replication and displayed virus entry blocking effect in Vero cells at low dose. In addition, Emetine could significantly reduce the lipopolysaccharide (LPS) induced interleukin-6 (IL-6) protein level and moderately reduce the tumor necrosis factor (TNF-?) protein level in the M1 polarized THP-1 macrophages. In vivo animal pharmacokinetics (PK) study revealed that Emetine was enriched in the lung tissue and had a long retention time (over 12?h). With 1?mg/kg single oral dose, the effective concentration of Emetine in lung was up to 1.8??M (mice) and 1.6??M (rats) at 12?h, which is over 200-fold higher than the EC(50) of the drug. The potent in vitro antiviral replication efficacy and the high enrichment in target tissue, combining with the well documented safety profiles in human indicate that low dose of Emetine might be a potentially effective anti-SARS-CoV-2 infection therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-020-00018-9. Twit Text FOAVip Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences ????Mol Biomed http://www.kidney.de/pget.php?&tw=1&pmid=34765997 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34765997 #FOAvip English Wikipedia <ref>{{Cite pmid|34765997 }}</ref> Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences #MMPMID34765997 Wang A ; Sun Y ; Liu Q ; Wu H ; Liu J ; He J ; Yu J ; Chen QQ ; Ge Y ; Zhang Z ; Hu C ; Chen C ; Qi Z ; Zou F ; Liu F ; Hu J ; Zhao M ; Huang T ; Wang B ; Wang L ; Wang W ; Wang W ; Ren T ; Liu J ; Sun Y ; Fan S ; Wu Q ; Liang C ; Sun L ; Su B ; Wei W ; Liu Q Mol Biomed 2020[]; 1 (1 ): 14 PMID34765997 show ga The global pandemic of COVID-19 has attracted extensive drug searching interets for the new coronavirus SARS-CoV-2. Although currently several of clinically used "old" drugs have been repurposed to this new disease for the urgent clinical investigation, there is still great demand for more effective therapies for the anti-infections. Here we report the discovery that an "old" drug Emetine could potently inhibit SARS-CoV-2 virus replication and displayed virus entry blocking effect in Vero cells at low dose. In addition, Emetine could significantly reduce the lipopolysaccharide (LPS) induced interleukin-6 (IL-6) protein level and moderately reduce the tumor necrosis factor (TNF-?) protein level in the M1 polarized THP-1 macrophages. In vivo animal pharmacokinetics (PK) study revealed that Emetine was enriched in the lung tissue and had a long retention time (over 12?h). With 1?mg/kg single oral dose, the effective concentration of Emetine in lung was up to 1.8??M (mice) and 1.6??M (rats) at 12?h, which is over 200-fold higher than the EC(50) of the drug. The potent in vitro antiviral replication efficacy and the high enrichment in target tissue, combining with the well documented safety profiles in human indicate that low dose of Emetine might be a potentially effective anti-SARS-CoV-2 infection therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-020-00018-9. ?Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: precli(epmc).pdf DeepDyve Pubget Overpricing